NCT01145937

Brief Summary

Rationale: Keratoconus is a progressive, non-inflammatory corneal disease in which irregular refractive properties of the cornea result in loss of visual acuity. Treatment is aimed at improving vision, principally using (rigid) contact lenses. With progression of the disease non-correctable refractive abnormalities and/or corneal scars arise. For these advanced stages of keratoconus, a corneal transplant is the only treatment modality. New surgical grafting modalities have been developed to create partial thickness grafts, according to the location of corneal pathology. For keratoconus, transplanting only the anterior corneal lamellae lowers long-term graft rejection rates. We utilize a method to enhance the safety of the grafting procedure while better visual outcomes are expected. Objective: To investigate the additional value of partial endothelial trepanation (PET) in an anterior lamellar keratoplasty (ALKP) procedure in terms of efficacy and safety in patients with keratoconus. Study design: A randomized controlled interventional trial Study population: Patients over 18 years old with keratoconus in whom contact lens correction is unsuccessful and who are not suitable for corneal crosslinking. Intervention: Patients will be randomly assigned to corneal grafting techniques; partial endothelial trepanation in addition to an anterior lamellar keratoplasty (i.e. the PET group) or a regular ALKP procedure. Study outcomes: Risk of per-operative perforation. Secondary, factors contributing to treatment safety and efficacy. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is no extra burden or risk associated with participation in this study. All measurements are part of normal clinical practice. Adequate experience is available with both surgical techniques. Study participation has no effect on donor selection. If partial endothelial trepanation (PET) is associated with lower complication rates and better visual outcomes, this might be beneficial in terms of morbidity.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

5 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 17, 2010

Completed
9 months until next milestone

Study Start

First participant enrolled

March 1, 2011

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

December 3, 2015

Status Verified

December 1, 2015

Enrollment Period

4.2 years

First QC Date

June 14, 2010

Last Update Submit

December 2, 2015

Conditions

Keywords

KeratoconusCorneal graftingCorneal transplantationAnterior Lamellar Keratoplasty

Outcome Measures

Primary Outcomes (1)

  • Peroperative corneal perforation

    Peroperative corneal perforation is the biggest drawback of currently utilized grafting procedures (ALKP, 20-30%). Our new technique is believed to be safer, by reducing the number of corneal perforations during surgery. Corneal perforation necessitates converting the procedure to a full-thickness graft with a less favourable long term rejection profile.

    During Surgery. From start to closure of surgical procedure approx. 2h

Secondary Outcomes (6)

  • Best corrected visual acuity one year post op

    One year post-op

  • Manifest refraction one year post op

    One year post-op

  • Contact lens use (soft/rigid/scleral) or spectacle use

    one year post-op

  • Self-rated improvement questionnaire

    One year post-op

  • Corneal endothelial function one year post op

    One year post-op

  • +1 more secondary outcomes

Study Arms (2)

PET

EXPERIMENTAL

Partial endothelial trepanation in addition to anterior lamellar keratoplasty. The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature.

Procedure: PET

DALK

ACTIVE COMPARATOR

Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.

Procedure: DALK

Interventions

PETPROCEDURE

Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty

Also known as: Busin
PET
DALKPROCEDURE

Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.

Also known as: ALK
DALK

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age equal or above 18 years
  • keratoconus as defined and classified by
  • presence of corneal thinning and protrusion on slit-lamp examination
  • topographic criteria according to KISA% index (\>100%)
  • mean corneal curvature map
  • decreased best corrected visual acuity due to corneal scarring or contact lens intolerance

You may not qualify if:

  • prior corneal surgery, cross linking, refractive surgery or other treatment modalities
  • (localized) corneal thickness \< 200 µm
  • associated corneal endothelial disease on specular microscopy as defined by:
  • \<1500 endothelial cells per mm2
  • polymegathism \> 0.3
  • pleomorphism \< 0.6 (all are measurements of endothelial dysfunction)
  • gross ophthalmic pathology surpassing keratoconus as cause of decreased visual acuity
  • keratoconus-like disease (keratoglobus, pellucid marginal degeneration)
  • associated corneal anomalies (microcornea, macrocornea, buphthalmos, Peters syndrome, ICE-syndrome etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Amphia Ziekenhuis

Breda, 4819 EV, Netherlands

Location

Westfries Gasthuis

Hoorn, 1620 AR, Netherlands

Location

UMCN St. Radboud

Nijmegen, 6500HB, Netherlands

Location

Rotterdam Eye Hospital

Rotterdam, 3000 LM, Netherlands

Location

University Medical Center Utrecht

Utrecht, 3508 GA, Netherlands

Location

MeSH Terms

Conditions

Keratoconus

Condition Hierarchy (Ancestors)

Corneal DiseasesEye Diseases

Study Officials

  • Allegonda Van der Lelij, MD PhD

    UMC Utrecht

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ophthalmologist

Study Record Dates

First Submitted

June 14, 2010

First Posted

June 17, 2010

Study Start

March 1, 2011

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

December 3, 2015

Record last verified: 2015-12

Locations